Chen Y, et al. - In metastatic pancreatic cancer, researchers assessed if a decline in carbohydrate antigen (CA)19-9 correlated with survival according to platelet level. Study participants included 174 patients with histologically diagnosed metastatic pancreatic cancer. According to findings, a 25% decrease at week 6 may be an early indicator for prognosis in patients with metastatic pancreatic cancer. In patients with platelet low tumors vs platelet high tumors, the link of CA19-9 decrease with pancreatic cancer survival was stronger. The data presented in this work showed a differential prognostic impact of CA19-9 by platelet level.